Does Bazett's formula underestimate the corrected QT interval during bradycardia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bazett's Formula and Bradycardia

No, Bazett's formula does not underreport during bradycardia—it actually overcorrects (overestimates) the QTc interval at heart rates below 60 bpm, falsely suggesting QT prolongation when none may exist.

The Problem with Bazett's Formula at Slow Heart Rates

Bazett's formula (QTc = QT/√RR) has well-documented limitations that vary depending on heart rate 1. The formula's accuracy is highest only between 60-100 bpm 1. Outside this range, systematic errors occur:

  • At heart rates <60 bpm (bradycardia): Bazett's formula overcorrects, producing falsely elevated QTc values 1
  • At heart rates >100 bpm (tachycardia): Bazett's formula undercorrects, producing falsely low QTc values 1

This means during bradycardia, you may incorrectly diagnose QT prolongation when the actual QT interval is normal.

Evidence from Research Studies

Multiple studies confirm this overcorrection pattern:

  • A pacemaker study examining drug-induced QT changes found that at heart rates slower than 60 bpm, Bazett's formula provided the most underestimated drug effect (ΔQTc) because the baseline QTc was already overestimated 2
  • A study of 210 healthy Turkish men demonstrated that at lower rates (<60 bpm), Bazett's formula underestimated the true QT interval relationship (meaning it overcorrected the QTc) 3
  • The Framingham Heart Study of 5,018 subjects showed Bazett's formula undercorrects at low heart rates, meaning it overcorrects the QTc value 4

Clinical Implications

The 2009 AHA/ACCF/HRS guidelines explicitly state that Bazett's formula leaves a strong positive residual correlation with heart rate and that adjusted QT values may be substantially in error, particularly at extreme heart rates 5. The guidelines recommend using linear regression functions rather than Bazett's formula for QT-rate correction 5.

The 2023 Canadian Cardiovascular Society guidelines reinforce this, noting that Bazett's formula has limitations including overcorrection at heart rates <60 bpm 1.

What to Use Instead

For bradycardic patients:

  • Fridericia's formula (QTc = QT/∛RR) performs better at slower heart rates than Bazett's, though it still has limitations 1
  • Hodges formula followed by the Nomogram method are most appropriate across all heart rates 2
  • Linear regression formulas (such as Framingham: QTc = QT + 0.154[1-RR]) more accurately correct for rate across the full spectrum 5, 4

Key Clinical Pitfall

Do not diagnose QT prolongation based solely on an automated Bazett's QTc in a bradycardic patient. The elevated value may be artifactual. Always:

  1. Manually verify the QT measurement using the tangent method
  2. Consider using an alternative correction formula (Fridericia, Hodges, or linear regression)
  3. Recognize that a QTc of 460-480 ms in a patient with HR <60 bpm may actually represent a normal QT interval

The most common error is falsely labeling bradycardic patients as having prolonged QT intervals when Bazett's formula is used uncritically.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.